Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use

AIMS: To explore the modifying effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysis of FIDELIO‐DKD and FIGARO‐DKD. MATERIALS AND METHODS: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Fonseca, Vivian, Umpierrez, Guillermo E., Caramori, Maria Luiza, Joseph, Amer, Lambelet, Marc, Lawatscheck, Robert, Bakris, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092103/
https://www.ncbi.nlm.nih.gov/pubmed/36193847
http://dx.doi.org/10.1111/dom.14883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092103/
https://www.ncbi.nlm.nih.gov/pubmed/36193847
http://dx.doi.org/10.1111/dom.14883

Ejemplares similares